Anna Turkina

5.0k total citations
134 papers, 1.5k citations indexed

About

Anna Turkina is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Anna Turkina has authored 134 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 125 papers in Hematology, 90 papers in Genetics and 35 papers in Rheumatology. Recurrent topics in Anna Turkina's work include Chronic Myeloid Leukemia Treatments (119 papers), Chronic Lymphocytic Leukemia Research (80 papers) and Eosinophilic Disorders and Syndromes (35 papers). Anna Turkina is often cited by papers focused on Chronic Myeloid Leukemia Treatments (119 papers), Chronic Lymphocytic Leukemia Research (80 papers) and Eosinophilic Disorders and Syndromes (35 papers). Anna Turkina collaborates with scholars based in Russia, United States and Germany. Anna Turkina's co-authors include Dong‐Wook Kim, Jörge E. Cortes, Carlo Gambacorti‐Passerini, Hagop M. Kantarjian, H. Jean Khoury, Tim H. Brümmendorf, Eric Leip, Steven Arkin, Charles Cunningham and Steven Novick and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Anna Turkina

114 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna Turkina Russia 17 1.2k 1.0k 544 296 234 134 1.5k
Phuong Dang Australia 12 1.4k 1.2× 1.1k 1.1× 643 1.2× 334 1.1× 178 0.8× 31 1.6k
Franck E. Nicolini France 19 1.5k 1.3× 1.2k 1.2× 697 1.3× 253 0.9× 195 0.8× 64 1.7k
Athena Countouriotis United States 14 1.6k 1.4× 1.4k 1.4× 943 1.7× 323 1.1× 178 0.8× 21 1.9k
Lydia Wunderle Germany 9 1.2k 1.0× 739 0.7× 538 1.0× 262 0.9× 193 0.8× 17 1.5k
Manuel Ayala Mexico 4 1.0k 0.9× 854 0.8× 548 1.0× 172 0.6× 103 0.4× 10 1.2k
Philippe Rousselot France 16 2.0k 1.7× 1.7k 1.6× 1.0k 1.8× 365 1.2× 253 1.1× 31 2.3k
Guillermo Garcia‐Manero United States 24 1.3k 1.1× 834 0.8× 271 0.5× 248 0.8× 532 2.3× 40 1.8k
Philipp D. le Coutre Germany 23 2.3k 1.9× 1.9k 1.9× 1.2k 2.2× 449 1.5× 194 0.8× 72 2.5k
M. Brigid Bradley‐Garelik United States 15 2.2k 1.9× 1.9k 1.8× 1.2k 2.3× 351 1.2× 190 0.8× 28 2.5k
Jiří Mayer Czechia 11 748 0.6× 679 0.7× 320 0.6× 161 0.5× 162 0.7× 48 1.0k

Countries citing papers authored by Anna Turkina

Since Specialization
Citations

This map shows the geographic impact of Anna Turkina's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Turkina with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Turkina more than expected).

Fields of papers citing papers by Anna Turkina

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Turkina. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Turkina. The network helps show where Anna Turkina may publish in the future.

Co-authorship network of co-authors of Anna Turkina

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Turkina. A scholar is included among the top collaborators of Anna Turkina based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Turkina. Anna Turkina is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Turkina, Anna, et al.. (2024). Evolution of therapeutic approaches in patients with chronic myeloid leukemia and T315I mutation. SHILAP Revista de lepidopterología. 19(4). 93–107.
3.
4.
5.
Chelysheva, Ekaterina, et al.. (2022). Withdrawal syndrome after tyrosine kinase inhibitors discontinuation in patients with chronic myeloid leukemia. Terapevticheskii arkhiv. 94(7). 836–843.
6.
Hughes, Timothy P., Nelma Cristina D. Clementino, Jeffrey H. Lipton, et al.. (2021). Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update. Leukemia. 35(6). 1631–1642. 26 indexed citations
7.
Turkina, Anna, Ekaterina Chelysheva, А К Голенков, et al.. (2020). A prospective study of the monitoring of patients with chronic myeloid leukemia upon withdrawal of tyrosine kinase inhibitor therapy. 65(4). 370–385. 5 indexed citations
8.
Gusarova, Galina A., et al.. (2020). Comparative Analysis of Cardiovascular Disorders in Patients with Chronic Myeloid Leukemia on Tyrosine Kinase Inhibitor Therapy. SHILAP Revista de lepidopterología. 13(1). 104–111. 1 indexed citations
9.
10.
Turkina, Anna, et al.. (2020). Diagnosis and Treatment of Clonal Myeloproliferative Neoplasms with Eosinophilia. SHILAP Revista de lepidopterología. 13(2). 161–169. 1 indexed citations
11.
Ionova, Tatyana, et al.. (2020). Quality of Life of Hematologists in the Russian Federation According to the RAND SF-36 Questionnaire. SHILAP Revista de lepidopterología. 13(4). 411–419. 2 indexed citations
12.
13.
14.
15.
Shuvaev, Vasily, et al.. (2016). PHARMACOECONOMIC MODELLING OF TARGET THERAPY CHRONIC MYELOGENOUS LEUKEMIA: EARLY AND LATE SWITCHING. Haematologica. 101. 835–835. 1 indexed citations
16.
Gusarova, Galina A. & Anna Turkina. (2016). Arterial Events in Patients with Chronic Myeloid Leukemia Receiving Treatment with Second Generation Tyrosine Kinase Inhibitors. Clinical oncohematology. 9(4). 474–484. 2 indexed citations
17.
Shuvaev, Vasily, et al.. (2015). Pharmacoeconomical Analysis of Chronic Myelogenous Leukemia Treatment Free Remission. Blood. 126(23). 3293–3293. 5 indexed citations
18.
Sudarikov, Andrey, et al.. (2014). СИНХРОННЫЕ И МЕТАХРОННЫЕ МИЕЛОИДНЫЕ И ЛИМФОИДНЫЕ ОПУХОЛИ. 86(7). 37–44.
19.
Turkina, Anna, et al.. (2013). The problem of adherence to therapy in chronic myeloid leukemia: understanding the patient and making a decision. SHILAP Revista de lepidopterología. 6(2). 157–165. 1 indexed citations
20.
Turkina, Anna, et al.. (2010). A rare complication of imatinib mesylate therapy: drug-induced pneumonitis. SHILAP Revista de lepidopterología. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Phuong Dang Breakdown of academic impact, for papers by Franck E. Nicolini Breakdown of academic impact, for papers by Athena Countouriotis Breakdown of academic impact, for papers by Lydia Wunderle Breakdown of academic impact, for papers by Manuel Ayala Breakdown of academic impact, for papers by Philippe Rousselot Breakdown of academic impact, for papers by Guillermo Garcia‐Manero Breakdown of academic impact, for papers by Philipp D. le Coutre Breakdown of academic impact, for papers by M. Brigid Bradley‐Garelik Breakdown of academic impact, for papers by Jiří Mayer
Rankless by CCL
2026